The 30% EF treatment induced the up-regulation of 4E-BP1, which inhibited the formation of the eIF4F complex, thereby suppressing the synthesis of abnormal proteins, including α-syn, a pathological feature of PD (Figure 10). The gene discussed is EIF4EBP1; the disease is Parkinson disease.